Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation

Transplant International

Volumn 28, Issue 9, 2015, Pages 1055-1065

  Vitale, Alessandro ^a   Spolverato, Gaya ^a   Burra, Patrizia ^a   De Feo, Tullia Maria ^b   Belli, Luca ^c   Donato, Francesca ^b   Baroni, Gianluca Svegliati ^d   Marianelli, Tania ^e   Picciotto, Antonio ^f   Toniutto, Pierluigi ^g   Bhoori, Sherrie ^h   Passigato, Nicola ⁱ   Lucà, Maria Grazia ^j   Russo, Francesco Paolo ^a   Cillo, Umberto ^a   Fagiuoli, Stefano ^j  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

^d Ancona Hospital   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f UNIVERSITY OF GENOA   (Italy)

^g UNIVERSITY OF UDINE   (Italy)

^h IRCCS   (Italy)

ⁱ Verona Hospital   (Italy)

^j PAPA GIOVANNI XXIII HOSPITAL   (Italy)

more..

Author keywords

cost effectiveness analysis; hepatitis C virus infection; liver transplantation; recurrent HCV; sofosbuvir

Indexed keywords

PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT;

ADULT; AGE; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG RESPONSE; FEMALE; GENOTYPE; GRAFT RECIPIENT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION PREVENTION; ITALY; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RECURRENT INFECTION; RETROSPECTIVE STUDY; SURVIVAL TIME; ADVERSE EFFECTS; CHRONIC DISEASE; COMPLICATION; COST BENEFIT ANALYSIS; ECONOMICS; END STAGE LIVER DISEASE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HOSPITAL ADMISSION; KAPLAN MEIER METHOD; LIVER FAILURE; MARKOV CHAIN; METHODOLOGY; MIDDLE AGED; PREOPERATIVE PERIOD; PROBABILITY; RECURRENT DISEASE; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; END STAGE LIVER DISEASE; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; ITALY; KAPLAN-MEIER ESTIMATE; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MARKOV CHAINS; MIDDLE AGED; PREOPERATIVE PERIOD; PROBABILITY; RECURRENCE; RESEARCH DESIGN; RETROSPECTIVE STUDIES; SOFOSBUVIR; TREATMENT OUTCOME; WAITING LISTS;

EID: 84938745831     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12591     Document Type: Article

References (33)

1. Howell J, Angus P, Gow P,. Hepatitis C recurrence: the Achilles heel of liver transplantation. Transpl Infect Dis 2014; 16: 1.
2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245.
3. Degasperi E, Aghemo A,. Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives. Hepat Med 2014; 6: 25.
4. Gane EJ, Stedman CA, Hyland RH, et al,. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 34.
5. Curry MP, Forns X, Chung RT, et al,. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 2015; 148: 100.
6. Messori A, Maratea D, Fadda V, Gatto R, Trippoli S,. An Italian perspective: studying the cost-effectiveness of sofosbuvir before completion of national price negotiations. Eur J Gastro Hepatol 2014; 26: 813.
7. Lim KC, Wang VW, Siddiqui FJ, et al,. Cost-effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria. Hepatology 2015; 61: 227.
8. Llovet JM, Bruix J,. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008; 48: 1312.
9. Llovet JM, Di Bisceglie AM, Bruix J, et al,. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698.
10. Hagan LM, Sulkowski MS, Schinazi RF,. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. Hepatology 2014; 60: 37.
11. Volk ML, Vijan S, Marrero JA,. A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am J Transplant 2008; 8: 839.
12. Vitale A, Volk ML, De Feo TM, et al,. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list. J Hepatol 2014; 60: 290.
13. Deuffic-Burban S, Deltenre P, Buti M, et al,. Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology 2012; 143: 974.
14. Ciccozzi M, Lo Presti A, Ciccaglione AR, Zehender G, Ciotti M,. Phylogeny and phylodinamic of Hepatitis C in Italy. BMC Infect Dis 2012; 12 (Suppl 2): S5.
15. Italian Gross Domestic Product. Available at: http://data.worldbank.org/indicator/NY.GDP.PCAP.CD accessed February 2015.
16. Shillcutt SD, Walker DG, Goodman CA, Mills AJ,. Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules. Pharmacoeconomics 2009; 27: 903.
17. Beck JR, Kassirer JP, Pauker SG,. A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method. Am J Med 1982; 73: 883.
18. GU Serie Generale n.283 5-12-2014. http://www.gazzettaufficiale.it/gazzetta/serie-generale/caricaDettaglio?dataPubblicazioneGazzetta=2014-12-05numeroGazzetta=283; accessed on February 5, 2015
19. Lim KC, Wang VW, Siddiqui FJ, et al,. Cost-effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria. Hepatology 2015; 61: 227.
20. Siegel JE, Weinstein MC, Russell LB, Gold MR,. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276: 1339.
21. Fenwick E, O'Brien BJ, Briggs A,. Cost-effectiveness acceptability curves-facts, fallacies and frequently asked questions. Health Econ 2004; 13: 405.
22. Angelico M, Cillo U, Fagiuoli S, et al,. Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching. Dig Liver Dis 2011; 43: 155.
23. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR,. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889.
24. Berenguer M, Prieto M, Rayon JM, et al,. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32 (4 Pt 1): 852.
25. Prieto M, Berenguer M, Rayon JM, et al,. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999; 29: 250.
26. Biggins SW, Terrault NA,. Should HCV-related cirrhosis be a contraindication for retransplantation? Liver Transpl 2003; 9: 236.
27. Price JC, Terrault NA,. Sofosbuvir and ribavirin use in wait-listed patients with hepatitis C should be selective. Liver Int 2015; 35: 7.
28. Donato MF, Monico S, Malinverno F, et al,. Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication? Liver Int 2015; 35: 1.
29. Zeuzem S, Dusheiko GM, Salupere R, et al,. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993.
30. Fontana RJ, Hughes EA, Bifano M, et al,. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant 2013; 13: 1601.
31. Charlton M, Gane E, Manns MP, et al,. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015; 148: 108.
32. Gane EJ, Agarwal K,. Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: "a flood of opportunity". Am J Transplant 2014; 14: 994.
33. A Phase 2, multicenter, open-label study to investigate the safety and efficacy of sofosbuvir/ledipasvir fixed-dose combination + ribavirin administered in subjects infected with chronic HCV who have advanced liver disease or are post-liver transplant. Clinical-trials.gov: NCT01938430. Accessed November 2013.